Patents by Inventor Jinglin WANG

Jinglin WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11979205
    Abstract: A method for configuring and updating random access resources in a multi-antenna multiple-input multiple-output (MIMO) environment is provided, including: initializing a base station; broadcasting, by the base station, the available RACH resources using an SIB2; initiating, by users who have data to be sent in an uplink, random access processes on the RACH resources configured by the base station; and redefining an S state, an I state, and a C state. Configuration of the RACH resources may be gradually and dynamically optimized according to the quantity of antennas of the base station and a utilization rate threshold of the RACH resources, so that waste of random access RACH resources is reduced provided that an MIMO system meets a required user/service access success probability; a utilization of the resources is improved by fully utilizing spatial diversity characteristics of the MIMO system.
    Type: Grant
    Filed: April 2, 2022
    Date of Patent: May 7, 2024
    Assignee: ZHEJIANG UNIVERSITY CITY COLLEGE
    Inventors: Jiantao Yuan, Rui Yin, Anping Wan, Tao Fang, Jinglin Wang, Tianmin Shan
  • Publication number: 20240114577
    Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive, from a base station, a radio resource control (RRC) reconfiguration message. The UE may reestablish a radio link control (RLC) entity based on receiving the RRC reconfiguration message and transmit an indication that the RLC entity has been reestablished at the UE. In some cases, the UE may receive a data message prior to receiving an acknowledgment for the indication that the RLC entity is reestablished. For example, the base station may retransmit the RRC reconfiguration message prior to sending an acknowledgment status report. The UE may discard the data message based on the data message being received prior to receiving the acknowledgment.
    Type: Application
    Filed: April 30, 2021
    Publication date: April 4, 2024
    Inventors: Jingming CHANG, Haojun WANG, Jinglin ZHANG, Zhuoqi XU
  • Publication number: 20230358638
    Abstract: An aero-engine bearing fault diagnosis method based on variational mode decomposition and residual network includes the following steps: collect signals in different positions and directions with vibration acceleration sensors, which will be used as sample data; convert the said sample data into the target data type through normalization, slicing, variational mode decomposition and labeling, to get a training sample set; build a 1D-Resnet model, input the training sample set into the said 1D-Resnet model for training and save the model parameters when the model converges; diagnose the aero-engine bearing fault with the trained 1D-Resnet model, to get the diagnostic results. The method diagnoses and analyzes faults of the bearings of the rotating mechanical parts in aero-engines based on variational mode decomposition and residual network, which improves the diagnostic accuracy, and can provide an accurate and reliable basis for maintenance workers.
    Type: Application
    Filed: January 25, 2022
    Publication date: November 9, 2023
    Applicant: ZHEJIANG UNIVERSITY CITY COLLEGE
    Inventors: Anping WAN, Jie YANG, Jiantao YUAN, Jinglin WANG, Tianmin SHAN, Zhihua GAN, Bo WANG, Ting CHEN, Guanqun LUO
  • Patent number: 11400199
    Abstract: A bioartificial liver (BAL) based on human induced pluripotent stem cells (iPSCs)-derived hepatocyte-like cells (HLCs) and a multilayer porous bioreactor is provided. The plasma separation/retransfusion loop part includes a blood input pipe, an exhaust pipe spring clamp, a blood input peristaltic pump, a heparin pump, a plasma separation column, a first pressure monitor, and a heater. The cell reactor/plasma component exchange double-loop part includes a plasma input peristaltic pump, and a semipermeable membrane exchange column, a plasma exchange peristaltic pump, a red blood cell (RBC) pool, a membrane lung, a multilayer porous bioreactor, a second pressure monitor, and a third pressure monitor arranged in a 37° C. dedicated incubator. An outlet of the third pressure monitor and a blood cell outlet are connected to an inlet of the first pressure monitor, and then connected to the heater and a blood output pipe in sequence.
    Type: Grant
    Filed: February 7, 2021
    Date of Patent: August 2, 2022
    Assignee: NANJING DRUM TOWER HOSPITAL
    Inventors: Jinglin Wang, Haozhen Ren, Yitao Ding, Xiaolei Shi
  • Publication number: 20220143293
    Abstract: A bioartificial liver (BAL) based on human induced pluripotent stem cells (iPSCs)-derived hepatocyte-like cells (HLCs) and a multilayer porous bioreactor is provided. The plasma separation/retransfusion loop part includes a blood input pipe, an exhaust pipe spring clamp, a blood input peristaltic pump, a heparin pump, a plasma separation column, a first pressure monitor, and a heater. The cell reactor/plasma component exchange double-loop part includes a plasma input peristaltic pump, and a semipermeable membrane exchange column, a plasma exchange peristaltic pump, a red blood cell (RBC) pool, a membrane lung, a multilayer porous bioreactor, a second pressure monitor, and a third pressure monitor arranged in a 37° C. dedicated incubator. An outlet of the third pressure monitor and a blood cell outlet are connected to an inlet of the first pressure monitor, and then connected to the heater and a blood output pipe in sequence.
    Type: Application
    Filed: February 7, 2021
    Publication date: May 12, 2022
    Applicant: Nanjing Drum Tower Hospital
    Inventors: Xiaolei SHI, Haozhen REN, Jinglin WANG, Yitao DING
  • Patent number: 10807979
    Abstract: A 4,5-disubstituted-1H-pyrrolo(2,3-f)quinolin-2,7,9-tricarboxylate compound, or an analog, or derivative thereof, having a structure of Formula I: R1 and R4 are each independently an atom or group selected from hydrogen, a linear or branched C1-8 alkyl group, a deuterated linear or branched C1-8 alkyl group, an aralkyl group, or a substituted aryl group; R2 is independently an atom or group selected from halogens, a linear or branched C1-8 alkoxy group, or a deuterated linear or branched C1-8 alkoxy group; and R3 is independently an atom or group selected from a linear or branched C1-8 alkoxy group, or a deuterated linear or branched C1-8 alkoxy group. The compound is useful as a reaction intermediate for the synthesis of PQQ. A process in which CAN is used as an oxidant in the synthesis of PQQ in existing patents and literatures is replaced. This makes the process cheaper and more efficient.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: October 20, 2020
    Assignee: SHANGDONG CAMASY BIOTECHNOLOGY CO., LTD.
    Inventors: Jinglin Wang, Song Qin, Zhenqiang Mu, Yang Li
  • Patent number: 10654859
    Abstract: A methanesulfonate polymorph of a 5-type phosphodiesterase inhibitor. The structure of the 5-type phosphodiesterase inhibitor is as shown in formula A: The methanesulfonate polymorph of the 5-type phosphodiesterase inhibitor includes the following diffraction peaks measured at 2? reflection angles in an X-ray powder diffraction pattern: 7.1750°±0.2°, 7.6299°±0.2°, 8.8588°±0.2°, 13.2310°±0.2°, 14.3754°±0.2°, 14.8440±0.2°, 15.2941°±0.2°, 17.1838°±0.2°, 20.0314°±0.2°, 20.8507°±0.2°, 21.2839°±0.2°, 21.7890°±0.2°, 22.2594°±0.2°, 23.0373±0.2°, 25.1243°±0.2°, 25.4244°±0.2°, 26.1530°±0.2°, 28.1210°±0.2°, 30.0135°±0.2°, 31.4809°±0.2°, 32.3619°±0.2°, 37.2410°±0.2°, 37.6388°±0.2° and 40.8286°±0.2°. The methanesulfonate of the 5-type phosphodiesterase inhibitor not only improves the activity of drugs, but also improves the water solubility and the bioavailability of the drugs, and makes up the blank of studies on drugs of the crystal form.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: May 19, 2020
    Assignee: JINAN MEILUWEI BIOTECHNOLOGY CO., LTD.
    Inventors: Jinglin Wang, Ruimei Yu, Qiongqiong Lian
  • Publication number: 20200071319
    Abstract: A 4,5-disubstituted-1H-pyrrolo(2,3-f)quinolin-2,7,9-tricarboxylate compound, or an analog, or derivative thereof, having a structure of Formula I: R1 and R4 are each independently an atom or group selected from hydrogen, a linear or branched C1-8 alkyl group, a deuterated linear or branched C1-8 alkyl group, an aralkyl group, or a substituted aryl group; R2 is independently an atom or group selected from halogens, a linear or branched C1-8 alkoxy group, or a deuterated linear or branched C1-8 alkoxy group; and R3 is independently an atom or group selected from a linear or branched C1-8 alkoxy group, or a deuterated linear or branched C1-8 alkoxy group. The compound is useful as a reaction intermediate for the synthesis of PQQ. A process in which CAN is used as an oxidant in the synthesis of PQQ in existing patents and literatures is replaced. This makes the process cheaper and more efficient.
    Type: Application
    Filed: May 19, 2017
    Publication date: March 5, 2020
    Inventor: Jinglin WANG
  • Publication number: 20190292192
    Abstract: A methanesulfonate polymorph of a 5-type phosphodiesterase inhibitor. The structure of the 5-type phosphodiesterase inhibitor is as shown in formula A: The methanesulfonate polymorph of the 5-type phosphodiesterase inhibitor includes the following diffraction peaks measured at 2? reflection angles in an X-ray powder diffraction pattern: 7.1750°±0.2°, 7.6299°±0.2°, 8.8588°±0.2°, 13.2310°±0.2°, 14.3754°±0.2°, 14.8440±0.2°, 15.2941°±0.2°, 17.1838°±0.2°, 20.0314°±0.2°, 20.8507°±0.2°, 21.2839°±0.2°, 21.7890°±0.2°, 22.2594°±0.2°, 23.0373±0.2°, 25.1243°±0.2°, 25.4244°±0.2°, 26.1530°±0.2°, 28.1210°±0.2°, 30.0135°±0.2°, 31.4809°±0.2°, 32.3619°±0.2°, 37.2410°±0.2°, 37.6388°±0.2° and 40.8286°±0.2°. The methanesulfonate of the 5-type phosphodiesterase inhibitor not only improves the activity of drugs, but also improves the water solubility and the bioavailability of the drugs, and makes up the blank of studies on drugs of the crystal form.
    Type: Application
    Filed: July 26, 2017
    Publication date: September 26, 2019
    Inventor: Jinglin WANG
  • Publication number: 20180033104
    Abstract: A method for applying for an official certificate through a single agency, wherein its local computer server and its foreign computer server are kept communication with each other, between the local computer server and the foreign computer server, there is provided with a time difference reminder and a conference video relay, and/or both the local office and the foreign office have case processing computer management information system which includes event monitor in which whenever receiving a new message, an additional event log is established, while only after the new message has been processed, the additional event log is no longer being remindered regularly. The present invention can keep quality work with lower cost, which benefits clients of both countries, benefits the united agency, and benefits economy of both countries.
    Type: Application
    Filed: September 18, 2017
    Publication date: February 1, 2018
    Inventors: Jinglin WANG, Heyi WANG